REVA Medical to Report Financial Results Through Q2 2011

SAN DIEGO, Calif. and SYDNEY, Australia, Aug. 9, 2011 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold a conference call to discuss the Company’s financial results through June 30, 2011 and its business outlook. Robert Stockman, Chairman and CEO, will host the call.

The call is scheduled for 7:00 pm US EDT on Tuesday, August 16, 2011 (or Wednesday 17 August 2011, 9:00 am AEST) and may be accessed within the United States by dialing 1-877-312-5413 five minutes prior to the scheduled start time. For callers in Australia, please dial 2 8223 9876. A replay of the conference call will be available on the Company’s website after the call.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA’s lead product, the ReZolve™ stent, combines REVA’s proprietary stent design with a proprietary polymer that is metabolised and cleared from the body. �The ReZolve stent is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of stent structure over time, the ReZolve stent may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA is in the process of finalising the design of its ReZolve stent and currently intends to initiate a pilot human clinical trial in the third quarter of 2011.�REVA will require regulatory approval before it can begin selling the ReZolve stent.

The REVA Medical, Inc. logo is available at http://ping.fm/PdIF5

CONTACT: Investor/Media Enquiries:

         United States:
         Cheryl Liberatore
         REVA Medical, Inc.
         Director, Investor Relations and Marketing
         +1 858 966-3045

         Australia:
         Kyahn Williamson & Rebecca Wilson
         Buchan Consulting
         +61 3 9866 4722

News

http://bit.ly/ocBpF9